← Jiangxi Fushine Pharmaceutical overview

Jiangxi Fushine Pharmaceutical vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Jiangxi Fushine Pharmaceutical Co Ltd (300497.CS)

Q3 202613 Jul – 28 Sep 2026

▲4

Fushine's profit surge, dividends, and new patent drive gains

First-half profit surge Fushine expects first-half net profit to jump 2,487% to 3,204% year-on-year, one of the strongest earnings rebounds on ChiNext. This huge profit growth makes the stock more attractive to investors and supports a higher share price.
This is the core fundamental driver behind the stock's recent strength.
Interim cash dividend proposed Controlling shareholder Bao Jianhua proposed a 2026 interim cash dividend of 0.5 yuan per 10 shares. Returning cash to shareholders signals confidence and can attract income-focused investors, helping support the stock price.
Dividend announcements are a direct capital return event that can lift investor sentiment.
Japanese patent for protein technology Fushine won a Japanese invention patent for its Fusarium oxysporum mycelial protein technology, adding to patents already held in China, South Korea, and the US. This strengthens its position in the fast-growing alternative protein market and supports long-term growth prospects.
The patent expands the company's technology moat and international business potential.
Q3 profit forecast turns positive Fushine expects first-three-quarter net profit of 350-430 million yuan, up 658-785% year-on-year, swinging from a loss to a profit. This confirms the strong earnings trend is continuing beyond the first half, giving investors more confidence.
The Q3 forecast extends the profit recovery story and reinforces the positive earnings trajectory.

August 202613 Jul – 28 Sep 2026

▲4

Fushine's profit surge, dividends, and new patent drive gains

First-half profit surge Fushine expects first-half net profit to jump 2,487% to 3,204% year-on-year, one of the strongest earnings rebounds on ChiNext. This huge profit growth makes the stock more attractive to investors and supports a higher share price.
This is the core fundamental driver behind the stock's recent strength.
Interim cash dividend proposed Controlling shareholder Bao Jianhua proposed a 2026 interim cash dividend of 0.5 yuan per 10 shares. Returning cash to shareholders signals confidence and can attract income-focused investors, helping support the stock price.
Dividend announcements are a direct capital return event that can lift investor sentiment.
Japanese patent for protein technology Fushine won a Japanese invention patent for its Fusarium oxysporum mycelial protein technology, adding to patents already held in China, South Korea, and the US. This strengthens its position in the fast-growing alternative protein market and supports long-term growth prospects.
The patent expands the company's technology moat and international business potential.
Q3 profit forecast turns positive Fushine expects first-three-quarter net profit of 350-430 million yuan, up 658-785% year-on-year, swinging from a loss to a profit. This confirms the strong earnings trend is continuing beyond the first half, giving investors more confidence.
The Q3 forecast extends the profit recovery story and reinforces the positive earnings trajectory.

Latest13 Jul – 28 Sep 2026

▲4

Fushine's profit surge, dividends, and new patent drive gains

First-half profit surge Fushine expects first-half net profit to jump 2,487% to 3,204% year-on-year, one of the strongest earnings rebounds on ChiNext. This huge profit growth makes the stock more attractive to investors and supports a higher share price.
This is the core fundamental driver behind the stock's recent strength.
Interim cash dividend proposed Controlling shareholder Bao Jianhua proposed a 2026 interim cash dividend of 0.5 yuan per 10 shares. Returning cash to shareholders signals confidence and can attract income-focused investors, helping support the stock price.
Dividend announcements are a direct capital return event that can lift investor sentiment.
Japanese patent for protein technology Fushine won a Japanese invention patent for its Fusarium oxysporum mycelial protein technology, adding to patents already held in China, South Korea, and the US. This strengthens its position in the fast-growing alternative protein market and supports long-term growth prospects.
The patent expands the company's technology moat and international business potential.
Q3 profit forecast turns positive Fushine expects first-three-quarter net profit of 350-430 million yuan, up 658-785% year-on-year, swinging from a loss to a profit. This confirms the strong earnings trend is continuing beyond the first half, giving investors more confidence.
The Q3 forecast extends the profit recovery story and reinforces the positive earnings trajectory.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

August 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

Latest31 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.